Physician profile
Jakrin Kewcharoen
NPI 1972097855
$23,820.77
in general payments reported to CMS, 2019-2025
8 companies · $10K in 2025
The $10K reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.33 · 2022: $140 · 2023: $6,205 · 2024: $7,124 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $13K · Food and Beverage: $5,936 · Grant: $3,333 · Education: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $13,220.48 |
| Food and Beverage | $5,936.39 |
| Grant | $3,333.34 |
| Education | $1,136.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $11,350.37 | 2023-2025 | Acticor 7 Vr-T Dx, Pamira, Edora 8 Dr-T |
| Medtronic, INC. | $7,292.24 | 2021-2025 | Micra, Aurora Ev-Icd Mri Surescan, Linq II |
| Boston Scientific Corporation | $2,693.79 | 2025 | Farapulse, Emblem Mri S-Icd, General - Tachy |
| Biosense Webster, INC. | $2,246.81 | 2024-2025 | Carto 3, Nuvision Ice Catheter |
| Shockwave Medical, INC | $139.66 | 2022 | |
| Atricure, INC. | $60.34 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| Abbvie INC. | $23.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.27 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jakrin Kewcharoen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.